Literature DB >> 28660629

Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records.

Li C Cheung1,2, Qing Pan1, Noorie Hyun2, Mark Schiffman2, Barbara Fetterman3, Philip E Castle4, Thomas Lorey3, Hormuzd A Katki2.   

Abstract

For cost-effectiveness and efficiency, many large-scale general-purpose cohort studies are being assembled within large health-care providers who use electronic health records. Two key features of such data are that incident disease is interval-censored between irregular visits and there can be pre-existing (prevalent) disease. Because prevalent disease is not always immediately diagnosed, some disease diagnosed at later visits are actually undiagnosed prevalent disease. We consider prevalent disease as a point mass at time zero for clinical applications where there is no interest in time of prevalent disease onset. We demonstrate that the naive Kaplan-Meier cumulative risk estimator underestimates risks at early time points and overestimates later risks. We propose a general family of mixture models for undiagnosed prevalent disease and interval-censored incident disease that we call prevalence-incidence models. Parameters for parametric prevalence-incidence models, such as the logistic regression and Weibull survival (logistic-Weibull) model, are estimated by direct likelihood maximization or by EM algorithm. Non-parametric methods are proposed to calculate cumulative risks for cases without covariates. We compare naive Kaplan-Meier, logistic-Weibull, and non-parametric estimates of cumulative risk in the cervical cancer screening program at Kaiser Permanente Northern California. Kaplan-Meier provided poor estimates while the logistic-Weibull model was a close fit to the non-parametric. Our findings support our use of logistic-Weibull models to develop the risk estimates that underlie current US risk-based cervical cancer screening guidelines. Published 2017. This article has been contributed to by US Government employees and their work is in the public domain in the USA. Published 2017. This article has been contributed to by US Government employees and their work is in the public domain in the USA.

Entities:  

Keywords:  HPV; Kaplan-Meier; cervical cancer; cumulative risk estimation; prevalence-incidence models

Mesh:

Year:  2017        PMID: 28660629      PMCID: PMC5583012          DOI: 10.1002/sim.7380

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  20 in total

1.  Semiparametric regression analysis of interval-censored data.

Authors:  E Goetghebeur; L Ryan
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

2.  When you look matters: the effect of assessment schedule on progression-free survival.

Authors:  Katherine S Panageas; Leah Ben-Porat; Maura N Dickler; Paul B Chapman; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2007-03-21       Impact factor: 13.506

3.  A joint model of persistent human papillomavirus infection and cervical cancer risk: Implications for cervical cancer screening.

Authors:  Hormuzd A Katki; Li C Cheung; Barbara Fetterman; Philip E Castle; Rajeshwari Sundaram
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2015-03-17       Impact factor: 2.483

4.  Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.

Authors:  Hormuzd A Katki; Walter K Kinney; Barbara Fetterman; Thomas Lorey; Nancy E Poitras; Li Cheung; Franklin Demuth; Mark Schiffman; Sholom Wacholder; Philip E Castle
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

Review 5.  Nonexperimental comparative effectiveness research using linked healthcare databases.

Authors:  Til Stürmer; Michele Jonsson Funk; Charles Poole; M Alan Brookhart
Journal:  Epidemiology       Date:  2011-05       Impact factor: 4.822

Review 6.  Mining electronic health records: towards better research applications and clinical care.

Authors:  Peter B Jensen; Lars J Jensen; Søren Brunak
Journal:  Nat Rev Genet       Date:  2012-05-02       Impact factor: 53.242

7.  Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia.

Authors:  J Belinson; Y L Qiao; R Pretorius; W H Zhang; P Elson; L Li; Q J Pan; C Fischer; A Lorincz; D Zahniser
Journal:  Gynecol Oncol       Date:  2001-11       Impact factor: 5.482

8.  Risk estimation for the next generation of prevention programmes for cervical cancer.

Authors:  Hormuzd A Katki; Sholom Wacholder; Diane Solomon; Philip E Castle; Mark Schiffman
Journal:  Lancet Oncol       Date:  2009-09-18       Impact factor: 41.316

9.  Effects of mid-point imputation on the analysis of doubly censored data.

Authors:  C G Law; R Brookmeyer
Journal:  Stat Med       Date:  1992-09-15       Impact factor: 2.373

10.  The age distribution of cancer and a multi-stage theory of carcinogenesis.

Authors:  P ARMITAGE; R DOLL
Journal:  Br J Cancer       Date:  1954-03       Impact factor: 7.640

View more
  14 in total

1.  Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.

Authors:  Philip E Castle; Walter K Kinney; Xiaonan Xue; Li C Cheung; Julia C Gage; Nancy E Poitras; Thomas S Lorey; Hormuzd A Katki; Nicolas Wentzensen; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

2.  Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.

Authors:  Megan A Clarke; Li C Cheung; Philip E Castle; Mark Schiffman; Diane Tokugawa; Nancy Poitras; Thomas Lorey; Walter Kinney; Nicolas Wentzensen
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

3.  Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.

Authors:  Megan A Clarke; Barbara Fetterman; Li C Cheung; Nicolas Wentzensen; Julia C Gage; Hormuzd A Katki; Brian Befano; Maria Demarco; John Schussler; Walter K Kinney; Tina R Raine-Bennett; Thomas S Lorey; Nancy E Poitras; Philip E Castle; Mark Schiffman
Journal:  J Clin Oncol       Date:  2018-01-22       Impact factor: 44.544

4.  A comparison of high-grade cervical abnormality risks in women living with and without human immunodeficiency virus undergoing routine cervical-cancer screening.

Authors:  Philip E Castle; Brian Befano; Mark Schiffman; Nicolas Wentzensen; Thomas Lorey; Nancy Poitras; Marianne Hyer; Li C Cheung
Journal:  Prev Med       Date:  2022-07-08       Impact factor: 4.637

5.  Multistate models for the natural history of cancer progression.

Authors:  Li C Cheung; Paul S Albert; Shrutikona Das; Richard J Cook
Journal:  Br J Cancer       Date:  2022-07-11       Impact factor: 9.075

6.  The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics.

Authors:  Julia C Gage; Tina Raine-Bennett; Mark Schiffman; Megan A Clarke; Li C Cheung; Nancy E Poitras; Nicole E Varnado; Hormuzd A Katki; Philip E Castle; Brian Befano; Malini Chandra; Greg Rydzak; Thomas Lorey; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-11-17       Impact factor: 4.090

7.  Risk of cervical precancer and cancer among uninsured and underserved women from 2009 to 2017.

Authors:  Mona Saraiya; Li C Cheung; Ashwini Soman; Jacqueline Mix; Kristy Kenney; Xiaojian Chen; Rebecca B Perkins; Mark Schiffman; Nicolas Wentzensen; Jacqueline Miller
Journal:  Am J Obstet Gynecol       Date:  2020-10-06       Impact factor: 8.661

8.  Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy.

Authors:  Maria Demarco; Li C Cheung; Walter K Kinney; Nicolas Wentzensen; Thomas S Lorey; Barbara Fetterman; Nancy E Poitras; Brian Befano; Philip E Castle; Mark Schiffman
Journal:  J Low Genit Tract Dis       Date:  2018-04       Impact factor: 1.925

9.  Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.

Authors:  Maria Demarco; Thomas S Lorey; Barbara Fetterman; Li C Cheung; Richard S Guido; Nicolas Wentzensen; Walter K Kinney; Nancy E Poitras; Brian Befano; Philip E Castle; Mark Schiffman
Journal:  J Low Genit Tract Dis       Date:  2017-10       Impact factor: 1.925

10.  Are CIN3 risk or CIN3+ risk measures reliable surrogates for invasive cervical cancer risk?

Authors:  R Marshall Austin; Agnieszka Onisko; Chengquan Zhao
Journal:  J Am Soc Cytopathol       Date:  2020-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.